Evidence map›Paper›PMID 36934638›Full record

ArticleTranslational oncology2023

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study.

Xuchen Zhang, Chuantao Zhang, Helei Hou, Yuming Zhang, Peng Jiang, Hai Zhou, Lele Wang, Na Zhou, Xiaochun Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 6 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 6 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xuchen ZhangDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266000, China; Qingdao Medical College, Qingdao University, Qingdao 266000, China.
Chuantao ZhangDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266000, China; Qingdao Medical College, Qingdao University, Qingdao 266000, China.
Helei HouDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266000, China; Qingdao Medical College, Qingdao University, Qingdao 266000, China.
Yuming ZhangQingdao Medical College, Qingdao University, Qingdao 266000, China.
Peng JiangQingdao Medical College, Qingdao University, Qingdao 266000, China.
Hai ZhouQingdao Medical College, Qingdao University, Qingdao 266000, China.
Lele WangQingdao Medical College, Qingdao University, Qingdao 266000, China.
Na ZhouDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266000, China; Qingdao Medical College, Qingdao University, Qingdao 266000, China.
Xiaochun ZhangDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266000, China; Qingdao Medical College, Qingdao University, Qingdao 266000, China. Electronic address: zxc9670@qdu.edu.cn.
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPD-1 blockade has been shown to have promising efficacy and acceptable safety profiles in advanced and metastatic gastric cancer; however, the efficacy and safety of neoadjuvant PD-1 blockade-based immunotherapy plus chemotherapy in locally advanced gastric cancer (LAGC) remain uncertain.

methodsWe performed a retrospective review of patients with LAGC who received neoadjuvant treatment followed by D2 radical resection at the Affiliated Hospital of Qingdao University from 2019 to 2021. The primary aim was to investigate the difference in pathological response rates between neoadjuvant PD-1 immunotherapy plus chemotherapy and neoadjuvant chemotherapy alone. Multivariable models for pathological complete response (pCR) were constructed to investigate the factors that facilitate pCR.

trial registrationQYFYWZLL27406.

resultsA total of 77 patients were included in the analysis, among whom 34 (44.2%) received neoadjuvant PD-1 blockade immunotherapy plus chemotherapy. A higher pCR rate was observed in the neoadjuvant PD-1 blockade immunotherapy plus chemotherapy group (8 of 34, 23.5% vs. 2 of 43, 4.7%, P=0.019). Multivariate logistic regression analysis of pCR revealed neoadjuvant PD-1 blockade plus chemotherapy regimen promoted pCR (OR 12.95, P=0.016). Regarding safety, 76.5% (26 of 34) of patients in the PD-1 blockade plus chemotherapy group and 76.7% (33 of 43) of patients in the chemotherapy group experienced treatment-related adverse events (TRAEs), and grade 3 or worse adverse events were 29.4% (10 of 34) and 34.9% (15 of 43), respectively.

conclusionNeoadjuvant PD-1 blockade plus chemotherapy induced a higher pCR rate than neoadjuvant chemotherapy, and the combined therapy was tolerable in LAGC patients.

Indexed as

Gastric cancerImmune checkpoint inhibitorsNeoadjuvant treatmentPD-L1Retrospective study

Identifiers

PMID36934638
PMCPMC10034143
OpenAlexW4327694278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.